Abstract library

609 results for "Somatostatin Receptor Scintigraphy".
#1048 The Additional Value of Somatostatin Receptor Scintigraphy During Preoperative Staging in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors.
Introduction: During diagnostic workup for non-functioning pancreatic neuroendocrine tumors (NF-pNET) both computed tomography scan (CT-scan) and somatostatin receptor scintigraphy (SRS) are made.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Anneke Jilesen
#1299 Clinical Value of Somatostatin Receptor Scintigraphy in the Management of Medullary Thyroid Carcinoma
Introduction: Medullary Thyroid Carcinoma (MTC) is a rare form of thyroid cancer. It represents 5 to 10 % of these cancers. MTC grows from specialized thyroid cells called para-follicular cells, or C-cells that secrete a hormone called calcitonin. Its prognosis is usually good. Recurrences can occur, requiring lifelong surveillance.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dorra Ben Sellem
#2282 Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Based on Clinical Follow-up and Results of NETest
Introduction: Neuroendocrine neoplasms of the appendix (ANEN) are one of the most commonly identified gastroentropancreatic tumours (GEP). The aim of this retrospective study was to review the value of Somatostatin Receptor Scintigraphy (SRS) in staging and imaging follow-up of patients with confirmed ANEN, NENG1 and NENG2 in single institution.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Sonia Konsek
#1874 Value of Somatostatin Receptor Imaging (SRI) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Base on Clinical Follow-Up
Introduction: Neuroendocrine neoplasms of the appendix are common GEP-NEN tumors.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sonia Konsek
#873 The Analysis of Immunohistochemistry Staining, Neuronspecific Enolase (NSE) Level and Somatostatin Receptor Scintigraphy of Gastroenteropancreatic Neuroendocrine Neoplasm Cases
Introduction: 99mTc-HYNIC-TYR3-OCTREOTIDE somatostatin receptor (SSR) scintigraphy has been used to diagnose gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN).
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Jiangyuan Yu
Authors: Yu J, Li J, Yang Z, ...
#120 Somatostatin receptors 1-5 expression in a large series of well-differentiated neuroendocrine tumors
Introduction: For their antisecretive and antiproliferative effect somatostatin analogs (SA) have been used in the treatment of neuroendocrine tumors (NETs), based on the expression of somatostatin receptors (sstRs). The potential availability of new SA for the treatment of patients with NETs suggests a better characterization of sstRs.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Paola Loli
#56 Somatostatinreceptor scintigraphy with Tc-99m-tektrotyd in patients with neuroendocrine tumors: correlation with immunohistochemistry
Introduction: Somatostatin receptor scintigraphy (STRS) with Tc-99m-tektrotyd has been used in the past few years for diagnosis and staging of neuroendocrine tumors (NETs). A number of clinicopathologic criteria proved to be useful predictors of malignant behavior of these tumors. Immunohistochemical markers for NETs include cell proliferation (Ki-67 index) and neuroendocrine markers such as chromogranin A (CgA) and synaptophysin.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Margarida Rodrigues
#365 FDOPA PET/CT has a Significant Clinical Impact on the Management of Patients with Neuroendocrine Tumors
Introduction: Studies suggest that positron emission tomography (PET) using the dopamine-synthesis tracer [18F]fluoro-dihydroxyphenylalanine (FDOPA) may improve the clinical management of patients with NET.
Conference:
Category: Basic
Presenting Author: Dr. Michael Sørensen
#997 Comparison of Different Diagnostic Methods for the Assessment of Progression in Patients with Neuroendocrine Tumors (NET)
Introduction: Different imaging and laboratory methods are used to evaluate patients with NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Florian Keplinger
#245 Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Apostolos V. Tsolakis
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.